PDCT-06. PHASE 1 STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH H3 K27M-MUTANT HIGH GRADE GLIOMA OR NEWLY DIAGNOSED DIPG

The imipridone ONC201 is the first selective antagonist of DRD2 for clinical oncology. Several Phase 1, Phase 1/2 and Phase 2 studies in patients with advanced cancers have established the single agent recommended Phase 2 dose (RP2D) of 625mg ONC201 administered orally once a week in adults. ONC201...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Gardner, Sharon, Suarez, Fernando, Stafford, James M, S. Tarapore, Rohinton, Merdinger, Krystal, Oster, Wolfgang, Allen, Joshua, S. Chi, Andrew, Fuller-Becker, Hope, Yaffe, Anna, C. Allen, Jeffrey
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217036/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.836
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky